Target- |
MechanismImmunostimulants |
|
|
|
Inactive Indication- |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.Austria |
First Approval Date01 Feb 2014 |
100 Clinical Results associated with FBM-Pharma GmbH
0 Patents (Medical) associated with FBM-Pharma GmbH
100 Deals associated with FBM-Pharma GmbH
100 Translational Medicine associated with FBM-Pharma GmbH